Clinical Pharmacokinetics

, Volume 43, Issue 9, pp 553–576 | Cite as

The MDR1 (ABCB1) Gene Polymorphism and its Clinical Implications

Leading Article

Abstract

There has been an increasing appreciation of the role of drug transporters in the pharmacokinetic and pharmacodynamic profiles of certain drugs. Among various drug transporters, P-glycoprotein, the MDR1 gene product, is one of the best studied and characterised. P-glycoprotein is expressed in normal human tissues such as liver, kidney, intestine and the endothelial cells of the blood-brain barrier. Apical (or luminal) expression of P-glycoprotein in these tissues results in reduced drug absorption from the gastrointestinal tract, enhanced drug elimination into bile and urine, and impeded entry of certain drugs into the central nervous system. The clinical relevance of P-glycoprotein depends on the localisation in human tissues (i.e. vectorial or directional movement), the therapeutic index of the substrate drug and the inherent inter- and intra-individual variability.

With regard to the variability, polymorphisms of the MDR1 gene have recently been reported to be associated with alterations in disposition kinetics and interaction profiles of clinically useful drugs, including digoxin, fexofenadine, Ciclosporin and talinolol. In addition, polymorphism may play a role in patients who do not respond to drug treatment. Moreover, P-glycoprotein is an important prognostic factor in malignant diseases, such as tumours of the gastrointestinal tract.

A growing number of preclinical and clinical studies have demonstrated that polymorphism of the MDR1 gene may be a factor in the overall outcome of pharmacotherapy for numerous diseases. We believe that further understanding the physiology and biochemistry of P-glycoprotein with respect to its genetic variations will be important to establish individualised pharmacotherapy with various clinically used drugs.

Notes

Acknowledgements

This paper was supported by a grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan (no. 13357020 to I.I.). The authors have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Roberts RL, Joyce PR, Mulder RT, et al. A common P-glycoprotein polymorphism is associated with nortriptylineinduced postural hypotension in patients treated for major depression. Pharmacogenetics J 2002; 2: 191–6CrossRefGoogle Scholar
  2. 2.
    Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetic study. Lancet 2002; 359: 30–6PubMedCrossRefGoogle Scholar
  3. 3.
    Siegsmund M, Brinkmann U, Schaffeier E, et al. Association of the P-glycoprotein transporter MDR1C3435T polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002; 13: 1847–54PubMedCrossRefGoogle Scholar
  4. 4.
    Illmer T, Schuler US, Thiede C, et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002; 62: 4955–62PubMedGoogle Scholar
  5. 5.
    Zheng H, Webber S, Zeevi A, et al. The MDR1 polymorphisms at exon 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol 2002; 63: 765–70PubMedCrossRefGoogle Scholar
  6. 6.
    Yamauchi A, Ieiri I, Kataoka Y, et al. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 2002; 74: 571–8PubMedCrossRefGoogle Scholar
  7. 7.
    Goto M, Masuda S, Saito H, et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 2002; 12: 451–7PubMedCrossRefGoogle Scholar
  8. 8.
    Nakamura T, Sakaeda T, Horinouchi M, et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 2002; 71: 297–303PubMedCrossRefGoogle Scholar
  9. 9.
    Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variants and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473–8PubMedCrossRefGoogle Scholar
  10. 10.
    Tanabe M, Ieiri I, Nagata N, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001; 297:1137–43PubMedGoogle Scholar
  11. 11.
    Kurata Y, Ieiri I, Kimura M, et al. Role of human MDRl gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002; 72: 209–29PubMedCrossRefGoogle Scholar
  12. 12.
    Siegmund W, Altmannsberger S, Paneitz A, et al. Effect of levothyroxine administration on intestinal P-glycoprotein expression: consequences for drug disposition. Clin Pharmacol Ther 2002; 72: 256–64PubMedCrossRefGoogle Scholar
  13. 13.
    Kim RB. MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. Pharmacogenetics 2002; 12: 425–7PubMedCrossRefGoogle Scholar
  14. 14.
    Germann UA. P-glycoprotein: a mediator of multidrug resistance in tumor cells. Eur J Cancer 1996; 32A: 927–44PubMedCrossRefGoogle Scholar
  15. 15.
    Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385–427PubMedCrossRefGoogle Scholar
  16. 16.
    Gottesman MM, Pastan I, Ambudkar SV. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 1996; 6: 610–7PubMedCrossRefGoogle Scholar
  17. 17.
    Goldstein LJ, Pastan I, Gottesman MM. Multidrug resistance in human cancer. Crit Rev Oncol Hematol 1992; 12: 243–53PubMedCrossRefGoogle Scholar
  18. 18.
    Cordon-Cardo C, O’Brien JP, Boccia J, et al. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990; 38: 1277–87PubMedCrossRefGoogle Scholar
  19. 19.
    Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987; 84:7735–8PubMedCrossRefGoogle Scholar
  20. 20.
    Borst P, Schinkel AH, Smith JJM, et al. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoprotein in mammals. Pharmacol Ther 1993; 60: 289–99PubMedCrossRefGoogle Scholar
  21. 21.
    Fojo AT, Ueda K, Salmon DJ, et al. Expression of a multidrugresistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 1987; 84: 265–9PubMedCrossRefGoogle Scholar
  22. 22.
    Sugawara I, Kataoka I, Morishita Y, et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistance gene as revealed by a monoclonal antibody, MRK16. Cancer Res 1988; 48: 1926–9PubMedGoogle Scholar
  23. 23.
    Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66: 85–94PubMedCrossRefGoogle Scholar
  24. 24.
    Klimecki WT, Futscher BW, Grogan TM, et al. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994; 83: 2451–8PubMedGoogle Scholar
  25. 25.
    Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101: 289–94PubMedCrossRefGoogle Scholar
  26. 26.
    Mayer U, Wagenaar E, Beijnen JH, et al. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by mdrla P-glycoprotein. Br J Pharmacol 1996; 119: 1038–44PubMedCrossRefGoogle Scholar
  27. 27.
    Nakamura Y, Ikeda S, Furukawa T, et al. Function of P-glycoprotein expressed in placenta and mole. Biochem Biophys Res Commun 1997; 235: 849–53PubMedCrossRefGoogle Scholar
  28. 28.
    Schinkel AH, Wagenaar E, Mol CA, et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97: 2517–24PubMedCrossRefGoogle Scholar
  29. 29.
    Cordon-Cardo C, O’Brien JP, Casals D, et al. Multidrugresistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989; 86: 695–8PubMedCrossRefGoogle Scholar
  30. 30.
    Schinkel AH, Mayer U, Wagenaar E, et al. Normal viability and altered pharmacokinetics in mice lacking mdrl-type (drugtransporting) P-glycoprotein. Proc Natl Acad Sci U S A 1997; 94: 4028–33PubMedCrossRefGoogle Scholar
  31. 31.
    Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 1997; 94: 2031–5PubMedCrossRefGoogle Scholar
  32. 32.
    Sugiyama Y, Kato Y, Chu X, et al. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemother Pharmacol 1998; 42 Suppl.: S44–9PubMedCrossRefGoogle Scholar
  33. 33.
    Schuetz EG, Yasuda K, Arimori K, et al. Human MDR1 and mouse mdrla P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene. Arch Biochem Biophys 1998; 350: 340–7PubMedCrossRefGoogle Scholar
  34. 34.
    Ito T, Yano I, Tanaka K, et al. Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther 1997; 282: 955–60PubMedGoogle Scholar
  35. 35.
    Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077–80PubMedGoogle Scholar
  36. 36.
    de Lannoy IA, Silverman M. The MDR1 gene product P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 1992; 189: 551–7PubMedCrossRefGoogle Scholar
  37. 37.
    Fromm MF, Kim RB, Stein CM, et al. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999; 99: 552–7PubMedCrossRefGoogle Scholar
  38. 38.
    Saeki T, Ueda K, Tanigawara Y, et al. P-glycoprotein-mediated transcellular transport of MDR-reversing agents. FEBS Lett 1993; 324: 99–102PubMedCrossRefGoogle Scholar
  39. 39.
    Pauli-Magnus C, von Richter O, Burk O, et al. Characterization of the major metabolites of Verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther 2000; 293: 376–82PubMedGoogle Scholar
  40. 40.
    Alsenz J, Steffen H, Alex R. Active apical secretory efflux of the HIV protease inhibitors are substrates for the MDR1 multidrug transporter. Pharm Res 1998; 15: 423–8PubMedCrossRefGoogle Scholar
  41. 41.
    Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 2003; 43: 285–307PubMedCrossRefGoogle Scholar
  42. 42.
    Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002; 54: 1295–310PubMedCrossRefGoogle Scholar
  43. 43.
    Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 2002; 34: 47–54PubMedCrossRefGoogle Scholar
  44. 44.
    Wacher J, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P4503A4 and p-glycoprotein: implications for drug delivery and cancer chemotherapy. Mol Carcinog 1995; 13: 129–34PubMedCrossRefGoogle Scholar
  45. 45.
    Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999; 16: 408–14PubMedCrossRefGoogle Scholar
  46. 46.
    Wacher VJ, Silverman JA, Zhang Y, et al. Role of P-glycoprotein and cytochrome P4503A in limiting oral absorption of Peptides and peptidomimetic. J Pharm Sci 1998; 87: 1322–30PubMedCrossRefGoogle Scholar
  47. 47.
    Sharom FJ. The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol 1997; 160: 161–75PubMedCrossRefGoogle Scholar
  48. 48.
    Gottesman MM, Hrycyna CA, Schoenlein PV, et al. Genetic analysis of the multidrug transporter. Annu Rev Genet 1995; 29: 607–47PubMedCrossRefGoogle Scholar
  49. 49.
    Mickley LA, Lee JS, Weng Z, et al. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 1998; 91: 1749–56PubMedGoogle Scholar
  50. 50.
    Ito S, Ieiri I, Tanabe M, et al. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001; 11:175–84PubMedCrossRefGoogle Scholar
  51. 51.
    Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169–74PubMedCrossRefGoogle Scholar
  52. 52.
    Kim RB, Leake BF, Choo EF, etal. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189–99PubMedCrossRefGoogle Scholar
  53. 53.
    Siegmund W, Ludwig K, Giessmann T, et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 2002; 72: 572–83PubMedCrossRefGoogle Scholar
  54. 54.
    Tang K, Ngoi S-M, Gwee P-C, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002; 12: 437–50PubMedCrossRefGoogle Scholar
  55. 55.
    Sakaeda T, Nakamura T, Horinouchi M, et al. MDR1 genotyperelated pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001; 18: 1400–4PubMedCrossRefGoogle Scholar
  56. 56.
    Ameyaw M-M, Regateiro F, Li T, et al. MDRl pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001; 11: 217–21PubMedCrossRefGoogle Scholar
  57. 57.
    Chowbay B, Cumaraswamy S, Cheung YB, et al. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003; 13: 89–95PubMedCrossRefGoogle Scholar
  58. 58.
    Schaeffeler E, Eichelbaum M, Brinkmann U, et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001; 358: 383–4PubMedCrossRefGoogle Scholar
  59. 59.
    Furuno T, Landi MT, Ceroni M, et al. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson’s disease. Pharmacogenetics 2002; 12: 529–34PubMedCrossRefGoogle Scholar
  60. 60.
    von Ahsen N, Richter M, Grupp C, et al. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A through concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47: 1048–52Google Scholar
  61. 61.
    Honda T, Dan Y, Koyabu N, et al. Polymorphism of MDR1 gene in healthy Japanese subjects: a novel SNP with an aminoacid substitution (Glu108Lys). Drug Metab Pharmacokinet 2002; 17: 479–81PubMedCrossRefGoogle Scholar
  62. 62.
    Lindholm A, Welsh M, Alton C, et al. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability. Clin Pharmacol Ther 1992; 52: 359–71PubMedCrossRefGoogle Scholar
  63. 63.
    Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62: 248–60PubMedCrossRefGoogle Scholar
  64. 64.
    Frassetto L, Mancinelli L, Christians U, et al. Fluconazoleinduced changes in tacrolimus oral bioavailability in three ethnic groups [abstract]. Millennial World Congress of Pharmaceutical Sciences; 2000 Apr 16–20; San FranciscoGoogle Scholar
  65. 65.
    Mancinelli LM, Frassetto LM, Floren LC, et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 2001; 69: 24–31PubMedCrossRefGoogle Scholar
  66. 66.
    Fitzsimmons WE, Bekersky I, Dressler D, et al. Demographic considerations in tacrolimus pharmacokinetics. Transplant Proc 1998; 30: 1359–64PubMedCrossRefGoogle Scholar
  67. 67.
    Elmore JG, Moceri VM, Carter D, et al. Breast carcinoma tumor characteristics in black and white women. Cancer 1998; 83: 2509–15PubMedCrossRefGoogle Scholar
  68. 68.
    Panwala CM, Jones JC, Viney JL. A novel model if inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdrla, spontaneously develop colitis. J Immunol 1998; 161: 5733–44PubMedGoogle Scholar
  69. 69.
    Maggio-Price L, Shows D, Waggie K, et al. Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drag resistance-deficient (mdrla-/-) mice. Am J Pathol 2002; 160: 739–51PubMedCrossRefGoogle Scholar
  70. 70.
    Schwab M, Schaeffeler E, Marx C, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003; 124: 26–33PubMedCrossRefGoogle Scholar
  71. 71.
    Rund D, Azar I, Shperling O. A mutation in the promoter of the multidrug resistance gene (MDR1) in human hematological malignancies may contribute to the pathogenesis of resistant disease. In: Kaspers GJL, Pieters RP, Veerman AJP, editors. Drug resistance in leukemia and lymphoma III. New York: Plenum Publishers, 1999: 71–5CrossRefGoogle Scholar
  72. 72.
    Stein U, Walther W, Wunderlich V. Point mutations in the mdr1 promoter of human osteosarcomas are associated with in vitro responsiveness to multidrug resistance relevant drugs. Eur J Cancer 1994; 30A: 1541–5PubMedCrossRefGoogle Scholar
  73. 73.
    Comwell MM, Smith DE. SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity. J Biol Chem 1993; 286: 19505–11Google Scholar
  74. 74.
    Cohen D, Yu L, Rzepka R, et al. Identification of two nuclear protein binding sites and their role in the regulation of the murine multidrug resistance mdrla promoter. DNA Cell Biol 1994; 13: 641–9PubMedCrossRefGoogle Scholar
  75. 75.
    van Groenigen M, Valentijn L, Baas F. Identification of a functional initiator sequence in the human MDR1 promoter. Biochim Biophys Acta 1993; 1172: 138–46PubMedCrossRefGoogle Scholar
  76. 76.
    Kerb R, Aynacioglu AS, Brockmoller J, et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J 2001; 1: 204–10PubMedCrossRefGoogle Scholar
  77. 77.
    Min DI, Ellingrod VL. C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther Drag Monit 2002; 24: 400–4CrossRefGoogle Scholar
  78. 78.
    Johne A, Kopke K, Gerloff T, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 2002; 72: 584–94PubMedCrossRefGoogle Scholar
  79. 79.
    Drescher S, Schaeffeler E, Hitzl M, et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002; 53: 526–34PubMedCrossRefGoogle Scholar
  80. 80.
    Goh BC, Lee SC, Wang LZ, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002; 20: 3683–90PubMedCrossRefGoogle Scholar
  81. 81.
    Potocnik U, Ravnik-Glavac M, Golouh R, et al. Naturally occurring mutations and functional polymorphisms in multidrug resistance 1 gene: correlation with microsatellite instability and lymphoid infiltration in colorectal cancers. J Med Genet 2002; 39: 340–6PubMedCrossRefGoogle Scholar
  82. 82.
    Hitzl M, Drescher S, van der Kuip H, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001; 11: 293–8PubMedCrossRefGoogle Scholar
  83. 83.
    Calado RT, Falcao RP, Garcia AB, etal. Influence of functional MDR1 gene polymorphisms on P-glycoprotein activity in CD34+ hematopoietic stem cells. Haematologica 2002; 87: 564–8PubMedGoogle Scholar
  84. 84.
    Meissner K, Sperker B, Karsten C, et al. Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy. J Histochem Cytochem 2002; 50: 1351–6PubMedCrossRefGoogle Scholar
  85. 85.
    Drach J, Gsur A, Hamilton G, et al. Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 1996; 88: 1747–54PubMedGoogle Scholar
  86. 86.
    Klimecki WT, Taylor CW, Dalton WS. Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by Verapamil isomers and cyclosporine A analogs. J Clin Immunol 1995; 15: 152–8PubMedCrossRefGoogle Scholar
  87. 87.
    Cvetkovic M, Leake B, Fromm MF, et al. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999; 27: 866–71PubMedGoogle Scholar
  88. 88.
    Tirona RG, Kin RB. Pharmacogenomics of organic anion-transporting Polypeptides (OATP). Adv Drug Deliv Rev 2002; 54: 1343–52PubMedCrossRefGoogle Scholar
  89. 89.
    Kimchi-Sarfaty C, Gribar JJ, Gottesman MM. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol 2002; 62: 1–6PubMedCrossRefGoogle Scholar
  90. 90.
    Kullak-Ublick GA, Ismair MG, Stieger B, et al. Organic aniontransporting Polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001; 120: 525–33PubMedCrossRefGoogle Scholar
  91. 91.
    Suzuki A, Tirona RG, Leake B, et al. Polymorphisms in the digoxin uptake transporter OATP-8, among Japanese, African-, and European-American subjects [abstract]. Clin Pharmacol Ther 2002; 71: P104CrossRefGoogle Scholar
  92. 92.
    Tirona RG, Leake BF, Merino G, et al. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001; 276(38): 35669–75PubMedCrossRefGoogle Scholar
  93. 93.
    Nishizato Y, Ieiri I, Suzuki H, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003; 73: 554–65PubMedCrossRefGoogle Scholar
  94. 94.
    Bailey DG, Malcolm J, Arnold O, et al. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998; 46: 101–10PubMedCrossRefGoogle Scholar
  95. 95.
    Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002; 71: 11–20PubMedCrossRefGoogle Scholar
  96. 96.
    Kobayashi D, Nozawa T, Imai K, et al. Involvement of human organic anion transporting Polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 2003; 306: 703–8PubMedCrossRefGoogle Scholar
  97. 97.
    Tamai I, Nezu J, Uchino H, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 2000; 273: 251–60PubMedCrossRefGoogle Scholar
  98. 98.
    Takanaga H, Ohnishi A, Matsuo H, et al. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice component in Caco-2 cells. Biol Pharm Bull 1998; 21: 1062–6PubMedCrossRefGoogle Scholar
  99. 99.
    Becquemont L, Verstuyft C, Kerb R, et al. Effect of grapefruit juice on digoxin pharmacokinetics in human. Clin Pharmacol Ther 2001; 70: 311–6PubMedGoogle Scholar
  100. 100.
    Judson R, Stephens JC, Windemuth A. The predicted power of haplotypes in clinical response. Pharmacogenomics 2000; 1: 15–26PubMedCrossRefGoogle Scholar
  101. 101.
    Stephens JC, Schneider JA, Tanguay DA, et al. Haplotype variation and linkage disequilibrium in 313 human genes. Science 2001; 293: 489–93PubMedCrossRefGoogle Scholar
  102. 102.
    Nakayama M, Wada M, Harada T, et al. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood 1998; 92: 4296–307PubMedGoogle Scholar
  103. 103.
    Mickley LA, Lee JS, Weng Z, et al. Gene rearrangement: a novel mechanism for MDR-1 gene activation. J Clin Invest 1997; 99: 1947–57PubMedCrossRefGoogle Scholar
  104. 104.
    Boyes J, Bird A. DNA methylation inhibits transcription indirectly via a methyl-CpG binding protein. Cell 1991; 64: 1123–34PubMedCrossRefGoogle Scholar
  105. 105.
    Laird PW, Jaenisch R. DNA methylation and cancer. Hum Mol Genet 1994; 3: 1487–95PubMedGoogle Scholar
  106. 106.
    Garcia-Manero G, Bueso-Ramos C, Daniel J, et al. DNA methylation patterns at relapse in adult acute lymphocytic leukemia. Clin Cancer Res 2002; 8: 1897–903PubMedGoogle Scholar
  107. 107.
    Tada Y, Wada M, Kuroiwa K, et al. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin Cancer Res 2000; 6: 4618–27PubMedGoogle Scholar
  108. 108.
    Kusaba H, Nakayama M, Harada T, et al. Association of 5′CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells. Eur J Biochem 1999; 262: 924–32PubMedCrossRefGoogle Scholar
  109. 109.
    Kantharidis P, El-Osta A, deSilva M, et al. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin Cancer Res 1997; 3: 2025–32PubMedGoogle Scholar
  110. 110.
    Lucia MB, Cauda R, Landay AL, et al. Transmembrane P-glycoprotein (P-gp/P-170) in HIV infection: analysis of lymphocyte surface expression and drug-unrelated function. AIDS Res Hum Retroviruses 1995; 11: 893–901PubMedCrossRefGoogle Scholar
  111. 111.
    Smit JW, Schinkel AH, Weert B, et al. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdrla and mdrlb genes have been disrupted. Br J Pharmacol 1998; 124: 416–24PubMedCrossRefGoogle Scholar
  112. 112.
    Schuetz EG, Umbenhauer DR, Yasuda K, et al. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes. Mol Pharmacol 2000; 57: 188–97PubMedGoogle Scholar
  113. 113.
    Srinivas RV, Middlemas D, Flynn P, et al. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother 1998; 42: 3157–62PubMedGoogle Scholar
  114. 114.
    Gutmann H, Fricker G, Drewe J, et al. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 1999; 56: 383–9PubMedGoogle Scholar
  115. 115.
    Carrillo JA, Ramos SI, Agundez JA, et al. Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: probe of CYP3A. Ther Drug Monit 1998; 20: 319–24PubMedCrossRefGoogle Scholar
  116. 116.
    Hashida T, Masuda S, Uemoto S, et al. Pharmacokinetic and prognostic significance of intestinal MDRl expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther 2001; 69: 308–16PubMedCrossRefGoogle Scholar
  117. 117.
    Schaich M, Pitter M, Illmer T, et al. Mutations in ras protooncogenes are associated with lower mdrl gene expression in adult acute myeloid leukaemia. Br J Haematol 2001; 112: 300–7PubMedCrossRefGoogle Scholar
  118. 118.
    Relling MV. Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Ther Drug Monit 1996; 18: 350–6PubMedCrossRefGoogle Scholar
  119. 119.
    Bart J, Groen HJ, Hendrikse NH, et al. The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev 2000; 26: 449–62PubMedCrossRefGoogle Scholar
  120. 120.
    Baekelandt MM, Holm R, Nesland JM, et al. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res 2000; 20: 1061–7PubMedGoogle Scholar
  121. 121.
    Van der Heuvel-Eibrink MM, Sonneveld P, Pieters R. The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther 2000; 38: 94–110PubMedGoogle Scholar
  122. 122.
    Lazarowski A, Sevlever G, Taratuto A, et al. Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. Pediatr Neural 1999; 21: 731–4CrossRefGoogle Scholar
  123. 123.
    Dhooge C, De Moerloose B, Laurey G, et al. P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: results of a 6-year prospective study. Br J Haematol 1999; 105: 676–83PubMedCrossRefGoogle Scholar
  124. 124.
    Chaudhary PM, Mechetner EB, Robinson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80: 2735–9PubMedGoogle Scholar
  125. 125.
    Coon JS, Wang Y, Bines SD, et al. Multidrug resistance activity in human lymphocytes. Hum Immunol 1991; 32: 134–40PubMedCrossRefGoogle Scholar
  126. 126.
    Kemnitz J, Uysal A, Haverich A, et al. Multidrug resistance in heart transplant patients: a preliminary communication on possible mechanisms of therapy-resistant rejection. J Heart Lung Transplant 1991; 10: 201–10PubMedGoogle Scholar
  127. 127.
    Zanker B, Barth C, Stachowski J, et al. Multidrug resistance gene MDRl expression: a gene transfection in vitro model and clinical analysis in cyclosporine-treated patients rejecting their grafts. Transplant Proc 1997; 29: 1507–8PubMedCrossRefGoogle Scholar
  128. 128.
    Midoneck SR, Etingin OR. Clarithromycin-related toxic effects of digoxin [letter]. N Engl J Med 1995; 333: 1505PubMedCrossRefGoogle Scholar
  129. 129.
    Brown BA, Wallace Jr RJ, Griffith DE, et al. Clarithromycinassociated digoxin toxicity in the elderly. Clin Infect Dis 1997; 24: 92–3PubMedCrossRefGoogle Scholar
  130. 130.
    Nawarskas JJ, McCarthy DM, Spinler SA. Digoxin toxicity secondary to Clarithromycin therapy. Ann Pharmacother 1977; 31: 864–6Google Scholar
  131. 131.
    Wakasugi H, Yano I, Ito T, et al. Effect of Clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 1998; 64: 123–8PubMedCrossRefGoogle Scholar
  132. 132.
    Yu KS, Yim DS, Cho JY, et al. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001; 69: 266–73PubMedCrossRefGoogle Scholar
  133. 133.
    Andersson T, Cederberg C, Edvardsson G, et al. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 1990; 47: 79–85PubMedCrossRefGoogle Scholar
  134. 134.
    Funck-Brentano C, Becquemont L, Leneveu A, et al. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. J Pharmacol Exp Ther 1997; 280: 730–8PubMedGoogle Scholar
  135. 135.
    Fromm MF, Busse D, Kroemer HK, et al. Differential induction of prehepatic and hepatic metabolism of Verapamil by rifampin. Hepatology 1996; 24: 796–801PubMedCrossRefGoogle Scholar
  136. 136.
    Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994; 26: 144–60PubMedCrossRefGoogle Scholar
  137. 137.
    Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 147–53PubMedCrossRefGoogle Scholar
  138. 138.
    Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001; 2: 9–39PubMedCrossRefGoogle Scholar
  139. 139.
    Sai K, Kaniwa N, Itoda M, et al. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotypedependent renal clearance of irinotecan. Pharmacogenetics 2003; 13: 741–57PubMedCrossRefGoogle Scholar
  140. 140.
    Kroetz DL, Pauli-Magnus C, Hodges LM, et al. Sequence diversity and haplotype structure in the human ANCN1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13: 481–94PubMedCrossRefGoogle Scholar
  141. 141.
    Skarke C, Jarrar M, Schmidt H, et al. Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 2003; 13: 651–60PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Department of Hospital Pharmacy, Faculty of MedicineTottori UniversityYonagoJapan

Personalised recommendations